M. Solinsky

Sub-nanomolar hMC1R agonists by end-capping of the melanocortin tetrapeptide His-D-Phe-Arg-Trp-NH(2).

D. Cross-Doersen, J. Knittel, F. H. Ebetino, 2003, Bioorganic & medicinal chemistry letters.

Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2)3CO-His-D-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?

D. Cross-Doersen, J. Knittel, F. H. Ebetino, 2004, Bioorganic & medicinal chemistry letters.

C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption.

J. Vacca, S. Gardell, S. D. Lewis, 1998, Bioorganic & medicinal chemistry letters.

Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles.

Lawrence C Kuo, Daniel R McMasters, Youwei Yan, 2008, Bioorganic & medicinal chemistry letters.

Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles.

S. D. Lewis, B. J. Lucas, A. Naylor-Olsen, 2006, Bioorganic & Medicinal Chemistry Letters.

Synthesis of Tic-D-Phe Psi[CH2-CH2] isostere and its use in the development of melanocortin receptor agonists.

Julie A Farmer, F. H. Ebetino, L. Gan, 2006, Bioorganic & medicinal chemistry letters.

Discovery of orally bioavailable 1,3,4-trisubstituted 2-oxopiperazine-based melanocortin-4 receptor agonists as potential antiobesity agents.

Julie A Farmer, M. Dowty, C. Obringer, 2008, Journal of medicinal chemistry.